检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:孙愚[1] 李帅[1] 罗婷[1] 郑鸿[1] 鄢希[1]
机构地区:[1]四川大学华西医院,618300
出 处:《实用癌症杂志》2016年第8期1355-1356,共2页The Practical Journal of Cancer
摘 要:目的探讨曲妥珠单抗联合新辅助化疗对表皮生长因子受体-2(HER-2)阳性乳腺癌患者的疗效。方法选取HER-2阳性乳腺癌患者58例,随机分为观察组和对照组,各29例。对照组给予表柔比星联合多西他赛的方案进行新辅助化疗,观察组在对照组的基础上给予曲妥珠单抗治疗。比较两组患者的近期、远期疗效。结果观察组有效率(RR)及病理完全缓解(p CR)率明显优于对照组,5年总生存率(OS)及5年无病生存率(DFS)明显高于对照组。结论曲妥珠单抗联合新辅助化疗治疗HER-2阳性乳腺癌近期疗效显著,并可有效改善患者预后,值得临床推广应用。Objective To investigate the efficacy of trastuzumab joint neoadjuvant chemotherapy for hers-2 positive breast cancer. Methods 58 hers-2 positive breast cancer patients were randomly divided into the observation group and the con- trol group, each with 29 cases. The control group was given epirubicin combined with docetaxel neoadjuvant chemotherapy, the ob- servation group on the basis of the control group was given trastuzumab. Short-term and long-term efficacy of the 2 groups were compared. Results Efficient (RR) and pathological complete response (pCR) rate of the observation group were significantly better than those of the control group ,the 5-year overall survival (OS) and 5-years disease-free survival (DFS) were significantly higher than those of the control group. Conclusion Trastuzumab joint neoadjuvant chemotherapy for hers-2 positive breast cancer has significant short-term efficacy, and can effectively improve the prognosis of patients, it is worthy of clinical popularization and application.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.13